Who is sponsoring NCT00021996?

NCT00021996 is sponsored by Dana-Farber Cancer Institute.

What condition does NCT00021996 study?

NCT00021996 studies Pain, Unspecified Adult Solid Tumor, Protocol Specific.

What is the status of NCT00021996?

NCT00021996 is currently COMPLETED.

Last reviewed 2013-07-17 · How we verify

Clinical Protocol for a Randomized Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Valdecoxib (SC-65872) 40mg BID as Add-On Therapy to Opioid Medication in Patients With Chronic Cancer Pain

NCT00021996 NA COMPLETED

RATIONALE: Valdecoxib may be effective in relieving chronic pain in cancer patients. It is not yet known if valdecoxib is effective in treating chronic pain. PURPOSE: Randomized clinical trial to study the effectiveness of valdecoxib in relieving chronic pain in cancer patients.

Details

Lead sponsor	Dana-Farber Cancer Institute
Phase	NA
Status	COMPLETED
Start date	2001-01
Completion	2004-02

Conditions

Pain
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

valdecoxib

Countries

United States